Page not found!

Sorry the page you are looking for no longer exists in this location.

We apologise for the inconvenience.

Please use the navigation on this page to locate other resources on this site.


Latest Headlines


BioInvent, ThromboGenics Initiate Patients Enrollment For Deep Vein Thrombosis

Study to assess safety and efficacy of three escalating doses of TB-402

Novo Nordisk Receives Marketing Authorisation For Victoza

Victoza, once-daily human Glucagon-Like Peptide-1 analogue, developed for the treatment of type 2 diabetes

Bayer Files Lawsuit Against Teva

Lawsuit concerns Teva's application for approval to market Levitra for the treatment of erectile dysfunction

Sanofi-aventis Receives FDA Approval For Multaq

Multaq to treat patients with atrial fibrillation or atrial flutter

Dow To Streamline Manufacturing Footprint

Calls for shutdown of a number of manufacturing assets, including ethylene and ethylene-derivative assets

J&J, Elan Sign Agreement For Alzheimer’s Immunotherapy Program

Collaboration to research, develop and commercialize selective products for treatment and prevention of neurodegenerative conditions

Emdeon Acquires eRx Network

New combined operation to be called eRx Network

Prasco Signs Distribution, Supply Agreement With Axcan Pharma

Prasco to market the authorized generic versions of URSO Forte Scored and URSO 250

Winner Medical Signs PurCotton Sales Agreement

Winner Medical to provide PurCotton raw materials, which will be processed into feminine products

MorphoSys Signs Agreement With University of Melbourne

MOR103, a HuCAL antibody against human GM-CSF, is currently in development for treatment of rheumatoid arthritis

Oncolytics Completes Patient Enrollment For Cancer Trial

The study demonstrated a clinical benefit rate of 75%

Genentech Reports Positive Phase-III Lucentis Study

Alcon Discontinues Trials For Anecortave Acetate

Eisai Provides Update On Aricept

Lixte Presents Positive Results For LB-1.2 Trial

Lundbeck Presents Positive Results For Depressive Disorder Phase II Study

Acura, King Receive FDA' Complete Response Letter For Acurox

More Articles...
More Products...

Comments & Opinion

Pandemic flu: gaps in preparedness remain

The current outbreak of influenza A (H1N1) is testing pandemic preparedness strategies across the globe. While widely implemented strategies seem to have prepared the world better than ever before, important gaps regarding the logistics of drug and vaccine distribution remain.

Neurology conference reports little progress in neurodegenerative disorders

The neurodegenerative disease market saw few major announcements at this year's recent American Academy of Neurology conference. While the Alzheimer's disease field must wait until next year before efficacy data from late-stage pipeline drugs are released, Parkinson's disease announcements were restricted to post-marketing studies designed to reposition treatments or protect vulnerable franchises.

Antiviral sales boosted as UAE prepares for influenza A (H1N1)

The recent outbreak of influenza A (H1N1) infection, previously referred to as swine flu, has thrown the spotlight on governments around the world and their ability to manage a pandemic. In the UAE, customers are currently finding it difficult to source antivirals but, with Dubai seen as a hub for international travel, the government has stockpiles ready for distribution should an outbreak occur.

Genentech/Roche: Avastin adds fifth indication to label

Following positive results from two Phase II trials, Genentech/Roche's Avastin has obtained accelerated FDA approval for glioblastoma patients who have progressed after previous treatment. While the commercial potential in this indication is small, it creates an opportunity for Avastin to become an established treatment in this type of brain cancer.

New oral multiple sclerosis drugs edge closer to market

With little market-shifting information announced across most neurological conditions at this year's AAN conference, it was left to the multiple sclerosis field to take center stage. Notably, Merck KGaA and Novartis presented positive Phase III data for their front running pipeline agents oral cladribine and FTY720 respectively. However, safety issues remain a concern for both products.

More Comments...
More Suppliers...



Newsletter Subscriptions

Advertise with us
Advertise with us